Leah Ensell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Leah Ensell has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Anne G. M. Schilder
UCL Ear Institute, University College London, 332 Grays Inn Road, London WC1X 8EE, UK
1 shared publication - Asma Awad
National Institute for Health Research, University College London Hospitals Biomedical Research Centre, London, UK
1 shared publication - Constantine Alifrangis
Department of Medical Oncology University College London Hospitals NHS Foundation Trust London UK
1 shared publication - Eleftheria Iliadou
First Department of Otorhinolaryngology and Head and Neck Surgery, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
1 shared publication - Helen Lowe
Experimental Cancer Medicine Centre Good Clinical Laboratory Practice Facility, Cancer Institute, University College London
1 shared publication - Marina Forbes
National Institute for Health Research, University College London Hospitals Biomedical Research Centre, London, UK
1 shared publication
Latest Publications
- Open Access
- 25 February 2026
- Published by Wolters Kluwer Health in Otology & Neurotology
- Vol. 47 (4) , 539-548
Early Detection of Ototoxicity Using Serial Mobile Audiometry, Otoacoustic Emissions Testing, and Inner Ear Biomarker Measurement in Patients Receiving Platinum-Based Chemotherapy Treatment: It is Feasible to Implement in a National Health Service (NHS) Cancer Ambulatory Care Setting
Importance: Platinum-based chemotherapy is widely used in the management of solid tumors, and up to 60% of patients will experience ototoxic side effects, including hearing loss and tinnitus. The advent of novel otoprotective drugs generates a need for more flexible and innovative real-time approaches to drug-induced ototoxicity monitoring in cancer patients. Objective: To assess the feasibility of recruitment and compliance to monitoring of ototoxicity with mobile out-of-booth audiometry, Distortion Product Otoacoustic Emission (DPOAE) testing, and serum biomarker measurements. Design: Prospective observational study. Setting: Cancer ambulatory care. Participants: Patients undergoing platinum-based chemotherapy for bone or testicular cancer. Results: Twenty-three patients were enrolled between February 2021 and June 2023. The mean age was 17.5 years (range: 13 to 36 y). Average compliance to monitoring assessments was 86.5% for audiometry, 84.8% for DPOAEs, and 84.3% for serum biomarker measurements. End-of-treatment audiometric changes indicative of ototoxicity were found in 18 (78.2%) of the participants. Conclusions and relevance: High compliance with serial mobile audiometry and otoacoustic emissions testing, and serum biomarker measurement suggests that ototoxicity monitoring can be successfully performed in cancer ambulatory care rather than in an audiology department setting. Further investigation is required to understand the role of serum prestin and otolin-1 in monitoring ototoxicity.
- 25 February 2026
- Published by Wolters Kluwer Health in Otology & Neurotology
- Vol. 47 (4) , 539-548
Open AccessEarly Detection of Ototoxicity Using Serial Mobile Audiometry, Otoacoustic Emissions Testing, and Inner Ear Biomarker Measurement in Patients Receiving Platinum-Based Chemotherapy Treatment: It is Feasible to Implement in a National Health Service (NHS) Cancer Ambulatory Care Setting
Importance: Platinum-based chemotherapy is widely used in the management of solid tumors, and up to 60% of patients will experience ototoxic side effects, including hearing loss and tinnitus. The advent of novel otoprotective drugs generates a need for more flexible and innovative real-time approaches to drug-induced ototoxicity monitoring in cancer patients. Objective: To assess the feasibility of recruitment and compliance to monitoring of ototoxicity with mobile out-of-booth audiometry, Distortion Product Otoacoustic Emission (DPOAE) testing, and serum biomarker measurements. Design: Prospective observational study. Setting: Cancer ambulatory care. Participants: Patients undergoing platinum-based chemotherapy for bone or testicular cancer. Results: Twenty-three patients were enrolled between February 2021 and June 2023. The mean age was 17.5 years (range: 13 to 36 y). Average compliance to monitoring assessments was 86.5% for audiometry, 84.8% for DPOAEs, and 84.3% for serum biomarker measurements. End-of-treatment audiometric changes indicative of ototoxicity were found in 18 (78.2%) of the participants. Conclusions and relevance: High compliance with serial mobile audiometry and otoacoustic emissions testing, and serum biomarker measurement suggests that ototoxicity monitoring can be successfully performed in cancer ambulatory care rather than in an audiology department setting. Further investigation is required to understand the role of serum prestin and otolin-1 in monitoring ototoxicity.